MGMT and astrocytoma (excluding glioblastoma): In this study, a preoperative and low-cost radiomics analysis was used to integrate imaging features from tumour and peritumoral oedema habitats on CE-T1-WI and T2-FLAIR images to predict MGMT promoter methylation in patients with grade II-IV astrocytoma.